One Canadian cannabis producer is crediting the high-profile failings of a competitor for its recent patient count achievement.

Last week, Geoffrey Benic, CEO of Aleafia Health (TSX:ALEF,OTCQX:ALEAF), informed shareholders that the company has reached an active patient base of 10,000 users for its medical products.


The company saw a 42 percent increase in its patient count during August and September, he said. In July, Aleafia Health had 7,000 patients.

“Growing our base of active, registered patients means increased sales of our high-margin, value-added product portfolio,” Benic said in a letter to investors.

Benjamin Ferdinand, CFO of Aleafia Health, told the Investing News Network (INN) that he attributes the company’s patient count growth to a variety of things, including the recent difficulties of some notable licensed producers (LPs) in the market.

“We’re able to very quickly take advantage of opportunities in the market,” he said.

When asked how significant the halt of medical product sales from CannTrust Holdings (NYSE:CTST,TSX:TRST) has been for his firm’s patient count growth, Ferdinand said the struggles of other producers have opened a prime spot for Aleafia Health.

“We’re extremely focused on our patients and making sure that they get the product that they deserve, so if another (LP) is not able to deliver that to them, we want to make sure that we give them the opportunity to continue their care, and we’re well positioned for that,” he said.

In July, CannTrust was found to have been growing cannabis in unlicensed rooms out of its Pelham, Ontario, facility. The scandal has followed the cannabis firm — and investors — since then.

Following the initial announcement, the firm halted all its sales to medical patients on July 10.

Before the unlicensed growing was flagged by Canadian regulators, CannTrust indicated its patient count amounted to 68,000 at the end of the firm’s Q1 2019.

Patients logging onto the CannTrust website today are faced with a warning message indicating the firm cannot sell any medical products.

Ferdinand told INN the company counts on its education platform to gain practitioner referrals for new patients. The executive said those referrals are really what are driving the patient uptick.

“The model is really built around education, referrals and high-quality service,” he said.

Ferdinand would not disclose an official guideline for the amount of patients the company expects to enroll by the end of the year; however, he added that Aleafia Health is forecasting more patient contact per month, serving as a chance to grow its count.

Nawan Butt, associate portfolio manager with Purpose Investments, told INN he agrees there are opportunities appearing from the failings of LPs such as CannTrust. But he reminded investors these advances don’t stand to make a significant impact at this stage.

“Even though there is room created because of a failing LP, that’s not where the majority of the low-hanging fruit is,” Butt said.

At this point of development in the Canadian cannabis marketplace — according to Butt — LPs are more aggressively competing with the black market options available to consumers, rather than seeking patient bases from each other.

“Yes, the failings of a single company will cause an opportunity for other companies, but I think it’s much more important to understand the context of the market as a whole,” he said.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Editorial Disclosure: The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Al Reese, Jr., to its Board of Directors

Mr. Reese has over 40 years experience in public and private businesses including as CFO of a formerly Nasdaq-listed energy company where he arranged finance transactions totaling over $10 billion dollars during his 20-year tenure. Mr. Reese was a Director and Chairman of the Audit Committee of a community bank in Texas for ten years until such time as it was acquired by a larger banking group in 2018.

Keep reading... Show less

Mexico looks to be closer than ever to cannabis reform, with the country releasing its regulation plans to make the drug legal in medical settings.

Meanwhile, despite the financial hardships seen recently in the Canadian cannabis market, CEOs in the country are still receiving top dollar, as per a new study.

Keep reading... Show less

Not for Distribution to United States Newswire Services or for Dissemination in the United States

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today the pricing of its previously announced best efforts overnight marketed offering (the “Offering”) of subordinate voting shares (the “Offered Securities”) of the Company at a price of C$16.00 per share for a total gross proceeds of approximately US$125 Million. The issue price represents a 3.3% discount to the last close of the Company’s subordinate voting shares traded on the Canadian Securities Exchange as of January 14, 2021. 100% of the Offering is expected to be purchased by a total of seven new and existing institutional investors, including current shareholder, Wasatch Global Investors.

Keep reading... Show less

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN) Red Light Holland (OTC: TRUFF) (CSE: TRIP) and Aphria, Inc. (NASDAQ: APHA).

Investors are cheering new and expected legislation which is opening new market opportunities for both cannabis and psychedelics globally. Innovation in premium branding, growing technologies, manufacturing, with operational execution are key, in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders in cannabis and psychedelics:

Keep reading... Show less

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$). The warrants have an exercise price of $6.58 per share, are immediately exercisable and will expire five years following the date of issuance. In connection with the Offering, the underwriter exercised in full its option to purchase an additional 274,285 shares of common stock and additional warrants to purchase 274,285 shares of common stock. The gross proceeds from the Offering were approximately $11.04 million, before deducting underwriting discounts and estimated offering expenses. No securities were offered or sold in Canada, including through the CSE or any other trading market in Canada

H.C. Wainwright & Co. (“Wainwright”) acted as the sole book-running manager for the Offering and is a non-related party to the Company.

Keep reading... Show less